Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers.
BACKGROUND
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumours with a typical 5 year survival rate of <40 %. DNA methylation in tumour-suppressor genes often occurs at an early stage of tumorigenesis, hence DNA methylation can be used as an early tumour biomarker. Saliva is an ideal diagnostic medium to detect early HNSCC tumour activities due to its proximity to tumour site, non-invasiveness and ease of sampling. We test the hypothesis that the surveillance of DNA methylation in five tumour-suppressor genes (RASSF1α, p16INK4a, TIMP3, PCQAP/MED15) will allow us to diagnose HNSCC patients from a normal healthy control group as well as to discriminate between Human Papillomavirus (HPV)-positive and HPV-negative patients.


METHODS
Methylation-specific PCR (MSP) was used to determine the methylation levels of RASSF1α, p16INK4a, TIMP3 and PCQAP/MED15 in DNA isolated from saliva. Statistical analysis was carried out using non-parametric Mann-Whitney's U-test for individually methylated genes. A logistic regression analysis was carried out to determine the assay sensitivity when combing the five genes. Further, a five-fold cross-validation with a bootstrap procedure was carried out to determine how well the panel will perform in a real clinical scenario.


RESULTS
Salivary DNA methylation levels were not affected by age. Salivary DNA methylation levels for RASSF1α, p16INK4a, TIMP3 and PCQAP/MED15 were higher in HPV-negative HNSCC patients (n = 88) compared with a normal healthy control group (n = 122) (sensitivity of 71 % and specificity of 80 %). Conversely, DNA methylation levels for these genes were lower in HPV-positive HNSCC patients (n = 45) compared with a normal healthy control group (sensitivity of 80 % and specificity of 74 %), consistent with the proposed aetiology of HPV-positive HNSCCs.


CONCLUSIONS
Salivary DNA tumour-suppressor methylation gene panel has the potential to detect early-stage tumours in HPV-negative HNSCC patients. HPV infection was found to deregulate the methylation levels in HPV-positive HNSCC patients. Large-scale double-blinded clinical trials are crucial before this panel can potentially be integrated into a clinical setting.
The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Yenkai
Y
Lim
The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Yunxia
Y
Wan
The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Dimitrios
D
Vagenas
Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Brisbane, QLD, 4072, Australia.
Dmitry A
DA
Ovchinnikov
Department of Otolaryngology, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Brisbane, QLD, 4102, Australia.|School of Medicine, University of Queensland, 288 Herston Road, Herston, Brisbane, QLD, 4006, Australia.
Chris F L
CF
Perry
Department of Biomedical Engineering, University of Melbourne, Parkville, Melbourne, VIC, 3010, Australia.
Melissa J
MJ
Davis
The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia. chamindie.punyadeera@qut.edu.au.
Chamindie
C
Punyadeera
Cross-fold validation and early detection; DNA methylation; Epigenetics biomarkers; Head and neck cancers; Human Papillomavirus; Saliva; Tumour-suppressor genes
Expert Rev Anticancer Ther. 2011 Sep;11(9):1321-5
21929305
Cell. 2012 Sep 14;150(6):1107-20
22980975
Psychiatr Genet. 2004 Sep;14(3):169-72
15318033
Clin Epigenetics. 2011 Aug;2(2):123-50
22704334
Oral Oncol. 2009 Apr-May;45(4-5):309-16
18804401
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
8790415
Leuk Res. 2000 Jan;24(1):39-46
10634644
Cancer Res. 2000 Feb 15;60(4):892-5
10706101
Anticancer Res. 2007 Jan-Feb;27(1A):283-8
17352245
Tumour Biol. 2014 Feb;35(2):943-8
23982879
BMC Cancer. 2016 Mar 03;16:178
26940728
J Dent Res. 2007 Feb;86(2):104-14
17251508
Ann Oncol. 2010 Oct;21 Suppl 7:vii243-5
20943622
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3635-40
14506151
J Clin Oncol. 2011 Nov 10;29(32):4294-301
21969503
PLoS One. 2013 Sep 20;8(9):e75283
24073258
Biomark Insights. 2014 Jul 03;9:53-60
25057238
Head Neck. 2012 Oct;34(10):1470-5
22106032
Br J Cancer. 1997;75(10):1410-6
9166931
Transl Oncol. 2012 Oct;5(5):321-6
23066440
Dent Clin North Am. 2011 Jan;55(1):159-78
21094724
J Med Life. 2009 Jul-Sep;2(3):303-7
20112475
Cancer Genet Cytogenet. 2007 Feb;173(1):31-7
17284367
Mol Biol Int. 2012;2012:701814
22530128
BMJ. 2010 Sep 20;341:c4684
20855405
N Engl J Med. 2008 Mar 13;358(11):1148-59
18337604
Clin Cancer Res. 2011 Jul 15;17(14):4782-9
21628494
Epigenetics. 2012 Nov;7(11):1279-89
23023649
Clin Cancer Res. 2012 Feb 15;18(4):1082-91
22228635
Semin Roentgenol. 2013 Jan;48(1):75-86
23158052
Biomark Med. 2016;10 (3):301-13
26888346
Acta Otorhinolaryngol Ital. 2013 Apr;33(2):77-87
23853396
J Mol Cell Biol. 2013 Feb;5(1):57-60
23014762
PLoS One. 2013 Oct 08;8(10):e76787
24116157
Clin Transl Med. 2012 Sep 05;1(1):19
23369566
Aust Dent J. 2011 Sep;56(3):253-6
21884139
Cancer Res. 2001 Apr 15;61(8):3410-8
11309301
Oncol Rep. 2012 Apr;27(4):1135-41
22246327
BMC Cancer. 2012 Jun 13;12:243
22695491
Clin Cancer Res. 2007 Feb 15;13(4):1179-85
17317827
Carcinogenesis. 2013 Jan;34(1):20-7
23042095
Diagn Pathol. 2013 Jul 02;8:110
23819566
Head Neck. 2009 Jan;31(1):1-8
19031408
Mol Biol Rep. 2014 Jun;41(6):3991-9
24566684
Clin Chem. 2011 May;57(5):675-87
21383043
J Transl Med. 2013 Dec 20;11:316
24359512
Oral Oncol. 2005 Sep;41(8):757-75
16109353
Curr Treat Options Oncol. 2012 Mar;13(1):35-46
22252884
PLoS One. 2009;4(3):e4941
19293934
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2396-405
18006929
BMC Public Health. 2010 Apr 16;10:196
20398380
Oral Oncol. 2014 Jun;50(6):587-92
24656975
Nat Commun. 2013;4:2513
24085110
Oral Oncol. 2009 Nov;45(11):e204-7
19631575
Biochem Med (Zagreb). 2014;24(2):258-65
24969919
Biotechniques. 2006 Jan;40(1):40, 42, 44 passim
16454038
J Clin Oncol. 2014 Oct 20;32(30):3349-52
25225434
Cancer Med. 2015 Apr;4(4):596-607
25644715
Lancet. 2008 May 17;371(9625):1695-709
18486742
Oncol Rep. 2009 Feb;21(2):507-13
19148529
Clin Cancer Res. 2011 Jun 1;17(11):3579-89
21505061
PLoS One. 2012;7(11):e48300
23139773
N Engl J Med. 2010 Jul 1;363(1):24-35
20530316
Clin Chim Acta. 2012 Jul 11;413(13-14):1066-70
22405932
Biotechniques. 2006 Feb;40(2):210-9
16526411
J Natl Cancer Inst. 2008 Mar 19;100(6):407-20
18334711
Cancer Lett. 2014 Jan 28;342(2):178-84
22388100